A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515706-77-00

Acronym

77242113PSO3006

Enrollment

399

Registered

2025-05-06

Start date

2025-05-08

Completion date

Unknown

Last updated

2025-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Plaque Psoriasis

Brief summary

IGA score of 0 or 1 and a ≥2 grade improvement from baseline at Week 16., PASI 90 at Week 16.

Interventions

DRUGSolution for injection without Ustekinumab 45

DRUGJNJ-77242113

DRUGFilm-Coated Tablet without JNJ-77242113

DRUGSTELARA 90 mg solution for injection in pre-filled syringe

DRUGSolution for injection in pre-filled syringe without Ustekinumab 90

DRUGSTELARA 45 mg solution for injection

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
IGA score of 0 or 1 and a ≥2 grade improvement from baseline at Week 16., PASI 90 at Week 16.	—

Countries

Austria, Belgium, Denmark, Germany, Hungary, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026